Massachusetts is currently home to 3150 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
NCT04598750
Recruiting
This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.
Gender:
ALL
Ages:
1 day and above
Trial Updated:
10/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Neonatal Thrombocytopenia, Bleeding
Register for Updates
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
NCT04045470
Recruiting
This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Giant Cell Tumor of Bone
Register for Updates
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605
Recruiting
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostat... Read More
Gender:
MALE
Ages:
Between 35 years and 74 years
Trial Updated:
10/05/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
NCT05203172
Recruiting
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Solid Tumors
Register for Updates
Prolonged Overnight Fasting And/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer
NCT06123988
Recruiting
The purpose of this study is to test if four different programs (prolonged overnighting fasting alone, exercise alone, a combination of prolonged overnight fasting and exercise, or general health education sessions alone) can reduce fatigue in women with advanced or metastatic breast cancer who are receiving a medication called a cyclin-dependent kinases-4 and 6 (CDK4/6) inhibitor.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
Add-on Reparixin in Adult Patients With ARDS
NCT05496868
Recruiting
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Acute Respiratory Distress Syndrome, Adult
Register for Updates
Digital Single Session Intervention for Youth Mental Health
NCT05449002
Recruiting
The aim of this study is to test the effectiveness of a single-session, digital intervention teaching the principle of practicing the opposite, when administered to youths on the waitlist for psychotherapy, with usual waitlist procedures as a control condition.
Gender:
ALL
Ages:
Between 9 years and 17 years
Trial Updated:
10/03/2024
Locations: Boston Child Study Center, Boston, Massachusetts
Conditions: Anxiety, Depression, Conduct Disorder, Stress
Register for Updates
Childhood Cancer Predisposition Study (CCPS)
NCT04511806
Recruiting
The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives. The central hypothesis is that studying individuals at high risk for childhood cancer creates a unique opportunity for improving the understanding of carcinogenesis, tumor surveillance, early detection, and cancer prevention, which will collectively contri... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/03/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pediatric Cancer
Register for Updates
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877
Recruiting
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Register for Updates